<DOC>
	<DOCNO>NCT00003416</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy kill tumor cell . Interferon alfa may interfere growth cancer cell . PURPOSE : Phase II trial study effectiveness high-dose melphalan plus peripheral stem cell transplantation follow interferon alfa treat patient Waldenstrom 's macroglobulinemia .</brief_summary>
	<brief_title>S9805 , High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed Interferon Alfa Treating Patients With Waldenstrom 's Macroglobulinemia</brief_title>
	<detailed_description>OBJECTIVES : I. Assess remission rate overall progression-free survival patient Waldenstrom 's macroglobulinemia treat tandem high dose melphalan support peripheral blood stem cell support . II . Assess associate hematologic nonhematologic toxicity regimen patient . OUTLINE : Regimen A ( dexamethasone induction ) : All patient receive high dose dexamethasone orally day 1-4 , 9-12 , 17-20 ; course repeat every 35 day total 3 course . Regimen B ( stem cell mobilization collection ) : Following 4-6 week break dexamethasone induction regardless response progression , patient stem cell collect follow administration filgrastim ( G-CSF ) injection ; G-CSF continue completion stem cell collection ( maximum 6 aphereses ) . Regimen C ( first peripheral blood stem cell transplant ( PBSCT ) ) : Regardless disease progression , patient recover toxicity dexamethasone induction stem cell mobilization collection , adequate number CD34 cell collect least 1 transplant , receive 1 dose melphalan daily 2 day follow peripheral stem cell reinfusion . G-CSF give injection begin day peripheral stem cell reinfusion continue absolute granulocyte count great 1,000/mm3 3 consecutive day . Regimen D ( second PBSCT ) : Patients adequate stem cell collection 2 transplant regimen B , evidence disease progression first transplant , recovered effect previous treatment undergo second treatment high dose melphalan PBSCT G-CSF support , give 3-12 month follow first transplant . Patients enough cell collect one transplant go directly regimen E. Regimen E ( maintenance interferon alfa ) : Beginning 5-12 week transplant upon hematologic recovery blood count toxicity , patient least partial response high dose melphalan PBSCT receive subcutaneous interferon alfa injection 3 time week 5 year disease progression , relapse , toxicity . Patients follow every month 6 month , every 3 month 5 year , annually thereafter . PROJECTED ACCRUAL : A total 60 patient accrue study 4 year .</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Immunologically diagnose Waldenstrom 's macroglobulinemia ( WM ) Evaluable quantifiable IgM One follow criterion must meet : 1 ) Patient demonstrate clinical symptom fatigue , dizziness , visual inacuity , hemorrhagic manifestation WM anemia , hyperviscosity , thrombocytopenia , coagulopathies 2 ) Advanced tumor mass present involve ONE following : Extensive lymphadenopathy ( great 2 cm ) Hepato splenomegaly palpable clinical examination Marked bone marrow infiltration great 50 % 3 ) Progressive disease ; i.e. , increase IgM concentration least 50 % , and/or drop great 2 g/dL hemoglobin ( absence gastrointestinal bleeding ) , and/or great 50,000/mm3 decrease platelet PATIENT CHARACTERISTICS : Age : Under 70 Performance status : SWOG 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Not specify Renal : Not specify Cardiovascular : At least 6 month since myocardial infarction No congestive heart failure No arrhythmia refractory therapy Ejection fraction within normal range MUGA ECHO Pulmonary : FEV1 least 50 % predict DLCO least 50 % predict Other : Not pregnant nursing Effective contraception require fertile patient No significant comorbid condition No uncontrolled lifethreatening infection No uncontrolled diabetes No malignancy within past 5 year except adequately treat basal squamous cell skin cancer , carcinoma situ cervix adequately treat stage I II cancer currently remission HIV negative Hepatitis B surface antigen negative PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since chemotherapy recover Endocrine therapy : Not specify Radiotherapy : At least 4 week since radiotherapy recover Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Waldenstr√∂m macroglobulinemia</keyword>
</DOC>